The JSC Clause Samples
POPULAR SAMPLE Copied 2 times
The JSC. 3.2.1 shall hold meetings in person as frequently as the members of the JSC may agree shall be necessary and otherwise by teleconference or a video-conference but in any event no less frequently than four times a Calendar Year, with the first such meeting occurring not later than 31 March and the third such meeting not later than 31 October in such Calendar Year. Dates of meetings shall be agreed by the Parties not less than thirty (30) days beforehand; responsibility for arranging the meetings, including, at least, providing notice and an agenda, shall be the responsibility of the Chairperson for that meeting; the first meeting of the JSC will take place as soon as practicable after the Effective Date and will be organised by GW Pharma;
3.2.2 shall by 31 October in each Calendar Year discuss and determine the Development Plan including the Lifecycle Management Plan as appropriate for the following Calendar Year based on the proposals of the Development Team and including any necessary change from the previous Calendar Year (if any) and the Program Budget therefor and each Party’s responsibilities for Program Costs thereunder. The Lifecycle Management Plan shall contain reasonable target dates for major events as appropriate, and the JSC shall discuss these in good faith with reference to progress made in the current Calendar Year. The JSC may add to and/or amend each Development Plan and Lifecycle Management Plan and Program Budget during the course of any Calendar Year as it considers appropriate from time to time, as long as each amendment is reduced to writing and signed and dated in accordance with the decision making process described in Clause 3.1.3 above. The JSC shall retain copies of all such authorised versions of the Development Plan and Lifecycle Management Plan and each shall become incorporated in this Agreement as of the date of signature by the JSC Chairperson;
3.2.3 shall by 31 October in each Calendar Year review the proposed Commercialisation Plan for the following Calendar Year proposed by the Brand Team. The JSC may, at the request of the Brand Team only, add to and/or amend each Commercialisation Plan during the course of any Calendar Year as it considers appropriate from time to time, as long as each amendment is reduced to writing and signed and dated in accordance with the decision making process described in Clause 3.1.3 above. The JSC shall retain copies of all such authorised versions of the Commercialisation Plan and each shal...
The JSC. As soon as practicable after the Effective Date, the Parties shall establish a Joint Steering Committee (the “JSC”). The JSC shall have review and oversight responsibilities for all research and development activities performed under this Agreement during the Research Term, as more specifically provided herein; provided, however, that the JSC shall have no authority to amend this Agreement. Each Party agrees to keep the JSC reasonably informed of its progress and activities during the Research Term. If GSK elects to exercise one of its Options pursuant to Article 4 with respect to a Pharmacopeia Development Compound, the JSC (and any applicable Subcommittee including, but not limited to, the Patent Subcommittee) shall continue as a vehicle to maintain information flow between GSK and Pharmacopeia regarding the progression of such compound as a GSK Development Compound, including by administering Patent matters pursuant to Article 8. Notwithstanding the above, all decisions with respect to the development, progression or commercialization of any such GSK Development Compound after GSK has exercised one of its Options with respect to such compound shall be at the sole discretion of GSK as the Party responsible under this Agreement for developing such compound, subject to GSK’s obligations of diligence as set forth in this Agreement.